These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26659397)

  • 1. Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy.
    Tannock IF; Sternberg CN
    Ann Oncol; 2016 Mar; 27(3):545-6. PubMed ID: 26659397
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to the letter to the editor 'Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy' by Tannock et al.
    Parker C; Gillessen S; Heidenreich A; Horwich A
    Ann Oncol; 2016 Apr; 27(4):750-1. PubMed ID: 26802159
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of initial local therapy on survival in men later receiving chemotherapy for prostate cancer: a population-based, propensity-weighted multivariable analysis.
    Zabell JR; Adejoro O; Jarosek SL; Elliott SP; Konety BR
    World J Urol; 2016 Oct; 34(10):1397-403. PubMed ID: 26914817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ['Men are not dying with, but from prostate cancer'].
    Stief C
    MMW Fortschr Med; 2014 Dec; 156(21-22):66. PubMed ID: 25608413
    [No Abstract]   [Full Text] [Related]  

  • 5. Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint.
    Birtle A
    Expert Rev Anticancer Ther; 2013 Jan; 13(1):89-99. PubMed ID: 23259430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate volume and its correlation with histopathological outcomes in prostate cancer.
    Sooriakumaran P; Srivastava A; Bhagat D; John M; Grover S; El-Douaihy Y; Rajan S; Leung R; Tewari A
    Urol Int; 2011; 86(2):152-5. PubMed ID: 21228543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
    Gravis G; Boher JM; Joly F; Soulié M; Albiges L; Priou F; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Culine S; Mourey L; Beuzeboc P; Habibian M; Oudard S; Fizazi K;
    Eur Urol; 2016 Aug; 70(2):256-62. PubMed ID: 26610858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prostate cancer].
    Ruah J
    Acta Med Port; 1999; 12(1-3):91-4. PubMed ID: 10423880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial comment. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.
    Bartoletti R; Cai T
    Urology; 2011 Mar; 77(3):e1; author reply e2. PubMed ID: 21376994
    [No Abstract]   [Full Text] [Related]  

  • 10. Cancer of the prostate--where are we now?
    Blandy J
    Practitioner; 1989 May; 233(1468):636, 639. PubMed ID: 2602296
    [No Abstract]   [Full Text] [Related]  

  • 11. Prostate disease in older men: 2. Cancer.
    Albertsen PC
    Hosp Pract (1995); 1997 Oct; 32(10):159-66, 171, 175-6 passim. PubMed ID: 9341640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer.
    Fitzpatrick JM
    Ir J Med Sci; 1987 May; 156(5):iii. PubMed ID: 3301734
    [No Abstract]   [Full Text] [Related]  

  • 13. The 18th International Symposium: Controversies in Prostate Cancer Diagnosis and Treatment.
    Pu YS; Fujimoto H; Kakizoe T; Myers R
    Jpn J Clin Oncol; 2005 Nov; 35(11):680-9. PubMed ID: 16275675
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostate cancer diagnosis.
    McLeod DG
    J Urol; 1995 May; 153(5):1570-1. PubMed ID: 7536269
    [No Abstract]   [Full Text] [Related]  

  • 15. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
    Gravis G; Boher JM; Chen YH; Liu G; Fizazi K; Carducci MA; Oudard S; Joly F; Jarrard DM; Soulie M; Eisenberger MJ; Habibian M; Dreicer R; Garcia JA; Hussain MHM; Kohli M; Vogelzang NJ; Picus J; DiPaola R; Sweeney C
    Eur Urol; 2018 Jun; 73(6):847-855. PubMed ID: 29475737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor focality in prostate cancer: implications for focal therapy.
    Karavitakis M; Ahmed HU; Abel PD; Hazell S; Winkler MH
    Nat Rev Clin Oncol; 2011 Jan; 8(1):48-55. PubMed ID: 21116296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treating 'healthy' men who have localised cancer of the prostate].
    de Jong IJ
    Ned Tijdschr Geneeskd; 2013; 157(42):A6703. PubMed ID: 24128601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic treatments for high-risk localized prostate cancer.
    Pignot G; Maillet D; Gross E; Barthelemy P; Beauval JB; Constans-Schlurmann F; Loriot Y; Ploussard G; Sargos P; Timsit MO; Vincendeau S; Pasticier G; Borchiellini D
    Nat Rev Urol; 2018 Aug; 15(8):498-510. PubMed ID: 29765147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More information on prostate specific antigen and prostate cancer.
    Stamey TA
    J Urol; 2003 Aug; 170(2 Pt 1):457-8. PubMed ID: 12853798
    [No Abstract]   [Full Text] [Related]  

  • 20. Prostate cancer.
    Guthrie TH; Watson P
    Am Fam Physician; 1987 Oct; 36(4):217-24. PubMed ID: 3314438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.